Research Article | Open Access
Wilfred P. Dela Cruz, Joann Y. Richardson, Judith M. Broestler, Jennifer A. Thornton, Patrick J. Danaher, "Rapid Determination of Macrolide and Lincosamide Resistance in Group B Streptococcus Isolated from Vaginal-Rectal Swabs", Infectious Diseases in Obstetrics and Gynecology, vol. 2007, Article ID 046581, 6 pages, 2007. https://doi.org/10.1155/2007/46581
Rapid Determination of Macrolide and Lincosamide Resistance in Group B Streptococcus Isolated from Vaginal-Rectal Swabs
Objective. Our objective was to assess the ability of real-time PCR to predict in vitro resistance in isolates of group B streptococcus (GBS). Methods. The first real-time PCR assays for the genes known to confer resistance to erythromycin and clindamycin in GBS were developed. Three hundred and forty clinical GBS isolates were assessed with these assays and compared with conventional disk diffusion. Results. The presence of an erythromycin ribosome methylation gene (ermB or ermTR variant A) predicted in vitro constitutive or inducible resistance to clindamycin with a sensitivity of 93% (95% CI 86%–97%), specificity of 90% (95% CI 85%–93%), positive predictive value of 76% (95% CI 67%–84%), and negative predictive value of 97% (95% CI 94%–99%). Conclusion. This rapid and simple assay can predict in vitro susceptibility to clindamycin within two hours of isolation as opposed to 18–24 hours via disk diffusion. The assay might also be used to screen large numbers of batched isolates to establish the prevalence of resistance in a given area.
- W. J. Morales, S. S. Dickey, P. Bornick, and D. V. Lim, “Change in antibiotic resistance of group B Streptococcus: impact on intrapartum management,” American Journal of Obstetrics and Gynecology, vol. 181, no. 2, pp. 310–314, 1999.
- S. Schrag, R. Gorwitz, K. Fultz-Butts, and A. Schuchat, “Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC,” MMWR Morbidity and Mortality Weekly Report, vol. 51, no. RR-11, pp. 1–22, 2002.
- B. Aracil, M. Miñambres, J. Oteo, M. de la Rosa, J. L. Gómez-Garcéz, and J. I. Alós, “Susceptibility of strains of Streptococcus agalactiae to macrolides and lincosamides, phenotype patterns and resistance genes,” Clinical Microbiology and Infection, vol. 8, no. 11, pp. 745–748, 2002.
- J. Clancy, J. Petitpas, F. Dib-Hajj et al., “Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes,” Molecular Microbiology, vol. 22, no. 5, pp. 867–879, 1996.
- J. S. Heelan, M. E. Hasenbein, and A. J. McAdam, “Resistance of group B Streptococcus to selected antibiotics, including erythromycin and clindamycin,” Journal of Clinical Microbiology, vol. 42, no. 3, pp. 1263–1264, 2004.
- Centers for Disease Control and Prevention, “Multi-level Antimicrobial Susceptibility Testing (MASTER),” November 2006, http://www.phppo.cdc.gov/dls/master/view_document.aspx?id=2.
- Centers for Disease Control and Prevention, “Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC),” MMWR Morbidity and Mortality Weekly Report, vol. 44, no. RR-12, pp. 1–13, 1995.
- M. G. Bergeron, D. Ke, C. Menard et al., “Rapid detection of group B streptococci in pregnant women at delivery,” New England Journal of Medicine, vol. 343, no. 3, pp. 175–179, 2000.
- National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. NCCLS Document M100-S14, vol. 24, Wayne, Pa, USA: National Committee for Clinical Laboratory Standards, 2004.
- H. Seppala, A. Nissinen, Q. Yu, and P. Huovinen, “Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland,” Journal of Antimicrobial Chemotherapy, vol. 32, no. 6, pp. 885–891, 1993.
- C. F. Arkin and M. S. Wachtel, “How many patients are necessary to assess test performance?” Journal of the American Medical Association, vol. 263, no. 2, pp. 275–278, 1990.
- D. J. Farrell, I. Morrissey, S. Bakker, and D. Felmingham, “Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study,” Journal of Antimicrobial Chemotherapy, vol. 50, 1, pp. 39–47, 2002.
- T. Horodniceanu, D. H. Bouanchaud, G. Bieth, and Y. A. Chabbert, “R plasmids in Streptococcus agalactiae (group B),” Antimicrobial Agents and Chemotherapy, vol. 10, no. 5, pp. 795–801, 1976.
- D. K. Warren, R. S. Liao, L. R. Merz, M. Eveland, and W. M. Dunne Jr., “Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay,” Journal of Clinical Microbiology, vol. 42, no. 12, pp. 5578–5581, 2004.
- A. J. Wright, “The penicillins,” Mayo Clinic Proceedings, vol. 74, no. 3, pp. 290–307, 1999.
- E. Bingen, C. Doit, P. Bidet, N. Brahimi, and D. Deforche, “Telithromycin susceptibility and genomic diversity of macrolide-resistant serotype III group B streptococci isolated in perinatal infections,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 2, pp. 677–680, 2004.
- K. Malathum, T. M. Coque, K. V. Singh, and B. E. Murray, “In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 4, pp. 930–936, 1999.
- J. J. González and A. Andreu, “Susceptibility of vertically transmitted group B streptococci to antimicrobial agents: multicenter study,” Enfermedades Infecciosas y Microbiologia Clinica, vol. 22, no. 5, pp. 286–291, 2004.
- R. Leclercq, “Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications,” Clinical Infectious Diseases, vol. 34, no. 4, pp. 482–492, 2002.
- G. K. Siberry, T. Tekle, K. Carroll, and J. Dick, “Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro,” Clinical Infectious Diseases, vol. 37, no. 9, pp. 1257–1260, 2003.
- B. Malbruny, A. M. Werno, T. P. Anderson, D. R. Murdoch, and R. Leclercq, “A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand,” Journal of Antimicrobial Chemotherapy, vol. 54, no. 6, pp. 1040–1044, 2004.
- Z. C. Acikgoz, E. Almayanlar, S. Gamberzade, and S. Gocer, “Macrolide resistance determinants of invasive and noninvasive group B Streptococci in a Turkish hospital,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 4, pp. 1410–1412, 2004.
- F. Fitoussi, C. Loukil, I. Gros et al., “Mechanisms of macrolide resistance in clinical group B streptococci isolated in France,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 6, pp. 1889–1891, 2001.
- F. Depardieu and P. Courvalin, “Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 1, pp. 319–323, 2001.
Copyright © 2007 Wilfred P. Dela Cruz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.